ImmunoFree Inc. Has Acquired Talaris Therapeutics, Inc.'s Tolerance Business; No Financial Terms Disclosed
Portfolio Pulse from Happy Mohamed
ImmunoFree, Inc. has acquired the rights to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1 Study from Talaris Therapeutics (TALS). ImmunoFree will now oversee all remaining close-out activities and the shutdown of the remaining active FREEDOM-1 phase 3 clinical sites. The company plans to commence a new clinical trial with modifications to the protocol to improve patient outcomes.
August 14, 2023 | 5:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Talaris Therapeutics has sold its rights to FCR001 and the FREEDOM-1 Study to ImmunoFree, Inc. This could potentially impact the company's future revenue streams.
The sale of the rights to FCR001 and the FREEDOM-1 Study by Talaris Therapeutics to ImmunoFree could potentially impact Talaris' future revenue streams, as these assets could have generated income for the company. The impact is negative as the company has lost a potential source of revenue.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100